Evidence map›Paper›PMID 38685685›Full record

ArticleJournal of cellular and molecular medicine2024

A potassium-chloride co-transporter with altered genome architecture functions as a suppressor in glioma.

Hongwei Liu, Zhouyang Pan, Xuelei Lin, Long Chen, Qi Yang, Wei Zhang, Luohuan Dai, Yihao Zhang, Wang Li, Yinhua Chen and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cellular and molecular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Hongwei LiuDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Zhouyang PanDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Xuelei LinDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Long ChenDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Qi YangDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Wei ZhangDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Luohuan DaiDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Yihao ZhangDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Wang LiDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Yinhua ChenDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Kang PengHunan International Scientific and Technological Cooperation Base of Brain Tumor Research, Xiangya Hospital, Central South University, Changsha, China.
Siyi WanggouDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Feiyue ZengDepartment of Radiology, Xiangya Hospital, Central South University, Changsha, China.
Xuejun LiDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.ORCID 0000-0001-6406-4423
Central South University · CN

Funding

National Natural Science Foundation of China 82270825
6 · The paper itself

Abstract

Gliomas, the most lethal tumours in brain, have a poor prognosis despite accepting standard treatment. Limited benefits from current therapies can be attributed to genetic, epigenetic and microenvironmental cues that affect cell programming and drive tumour heterogeneity. Through the analysis of Hi-C data, we identified a potassium-chloride co-transporter SLC12A5 associated with disrupted topologically associating domain which was downregulated in tumour tissues. Multiple independent glioma cohorts were included to analyse the characterization of SLC12A5 and found it was significantly associated with pathological features, prognostic value, genomic alterations, transcriptional landscape and drug response. We constructed two SLC12A5 overexpression cell lines to verify the function of SLC12A5 that suppressed tumour cell proliferation and migration in vitro. In addition, SLC12A5 was also positively associated with GABA

Indexed as

Brain NeoplasmsCell ProliferationGene Expression Regulation, NeoplasticGliomaK Cl- CotransportersSymportersCell Line, TumorCell MovementHumansPrognosisReceptors, GABA-AK Cl- CotransportersReceptors, GABA-ASLC12A5 protein, humanSymportersGABAgliomaimmunotherapymicroenvironmenttopologically associating domain

Identifiers

PMID38685685
PMCPMC11058328
OpenAlexW4396533599

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.